Price
Frequently asked questions
What is Novocure's market capitalization?
What is the Earnings Per Share (EPS) for Novocure?
What are the analyst ratings and target price for Novocure's stock?
What is Novocure's revenue over the trailing twelve months?
What is the EBITDA for Novocure?
What is the free cash flow of Novocure?
What is the 5-year beta of Novocure's stock?
How many employees does Novocure have, and what sector and industry does it belong to?
What is the free float of Novocure's shares?
Financials
Market Cap
$1.82B5Y beta
0.68EPS (TTM)
-$1.394Free Float
98.19MRevenue (TTM)
$577.74MEBITDA (TTM)
-$146.04MFree Cashflow (TTM)
-$78.21MPricing
Analyst Ratings
The price target is $27.42 and the stock is covered by 7 analysts.
Buy
3
Hold
4
Sell
0
Information
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
1,453
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker